Tuesday - July 8, 2025

LOGIN  |  REGISTER
Terns Pharmaceuticals
Terns Pharmaceuticals

CareCloud Leadership to Explore the Transformative Power of Generative AI in Healthcare in Upcoming Fireside Chats

June 20, 2023 | Last Trade: US$2.36 0.10 -4.07

SOMERSET, N.J., June 20, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced today that Hadi Chaudhry, CareCloud president and chief executive officer, and Bill Korn, chief strategy officer and acting chief financial officer, will be representing the company in two fireside chats on Thursday, June 22, 2023. The purpose of these discussions is to explore the transformative power of generative artificial intelligence in the healthcare industry.

To register for these events or to learn more about upcoming events, please visit CareCloud's investor relations site, ir.carecloud.com/news-events/ir-calendar.

About CareCloud

CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.

Follow CareCloud on LinkedInTwitter and Facebook.

SOURCE CareCloud

Company Contact:
Bill Korn
Chief Strategy Officer
CareCloud
bkorn@carecloud.com

Investor Contact:
Asher Dewhurst
ICR Westwicke
CareCloudIR@westwicke.com

Media Inquiries:
Alexis Feinberg
ICR Westwicke
CareCloudPR@westwicke.com

Terns Pharmaceuticals

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page